Neumann Mark's Form 4 filing
Intra-Cellular Therapies, Inc. (ITCI) · filed Feb 27, 2023
- Accession no.
- 0001209191-23-013442
- Filed
- Feb 27, 2023
- Trade date
- Feb 23-24, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $190.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Neumann MarkCIK 0001756211 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2023 | Common Stock | MOption exerciseAcquired | +7,906 | – | – | 60,486 | Direct | |
| Feb 24, 2023 | Common Stock | SSaleDisposed | −4,046 | $47.12 | −$190,647.52 | 56,440 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2023 | Common Stock | MOption exerciseDisposed | −7,906 | $0.00 | $0 | 7,907 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.